135 related articles for article (PubMed ID: 18196892)
1. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors.
Binderup T; Knigge U; Mellon Mogensen A; Palnaes Hansen C; Kjaer A
Neuroendocrinology; 2008; 87(4):223-32. PubMed ID: 18196892
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.
Mundschenk J; Unger N; Schulz S; Höllt V; Schulz S; Steinke R; Lehnert H
J Clin Endocrinol Metab; 2003 Nov; 88(11):5150-7. PubMed ID: 14602742
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
6. [The role of echoendoscopy and scintigraphy of somatostatin receptors in the staging of neuro-endocrine digestive tumors].
Giovannini M; Pasquier J; Brenot-Rossi I; Perrier H; Sauvan R; Seitz JF
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):109-13. PubMed ID: 7618832
[No Abstract] [Full Text] [Related]
7. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
[TBL] [Abstract][Full Text] [Related]
9. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.
Reubi JC; Waser B; Cescato R; Gloor B; Stettler C; Christ E
J Clin Endocrinol Metab; 2010 May; 95(5):2343-50. PubMed ID: 20228164
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
Dalm VA; Hofland LJ; Mooy CM; Waaijers MA; van Koetsveld PM; Langerak AW; Staal FT; van der Lely AJ; Lamberts SW; van Hagen MP
J Nucl Med; 2004 Jan; 45(1):8-16. PubMed ID: 14734660
[TBL] [Abstract][Full Text] [Related]
11. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy.
Papotti M; Croce S; Bellò M; Bongiovanni M; Allìa E; Schindler M; Bussolati G
Virchows Arch; 2001 Dec; 439(6):787-97. PubMed ID: 11787852
[TBL] [Abstract][Full Text] [Related]
12. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
13. First clinical evidence that imaging with somatostatin receptor antagonists is feasible.
Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2011 Sep; 52(9):1412-7. PubMed ID: 21852357
[TBL] [Abstract][Full Text] [Related]
14. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
15. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
19. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
Virgolini I; Traub T; Leimer M; Novotny C; Pangerl T; Ofluoglu S; Halvadjieva E; Smith-Jones P; Flores J; Li SR; Angelberger P; Havlik E; Andreae F; Raderer M; Kurtaran A; Niederle B; Dudczak R
Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
[TBL] [Abstract][Full Text] [Related]
20. [Pre- and intraoperative localization of neuroendocrine tumors].
Adams S; Baum RP; Adams M; Wenisch H; Schumm-Draeger PM; Encke A; Usadel KH; Hör G
Acta Med Austriaca; 1997; 24(2):81-6. PubMed ID: 9273812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]